Targeting the Four Pillars of Enterohepatic Bile Salt Cycling; Lessons From Genetics and Pharmacology
Overview
Affiliations
Bile salts play a pivotal role in lipid homeostasis, are sensed by specialized receptors, and have been implicated in various disorders affecting the gut or liver. They may play a role either as culprit or as potential panacea. Four very efficient transporters mediate most of the hepatic and intestinal bile salt uptake and efflux, and are each essential for the efficient enterohepatic circulation of bile salts. Starting from the intestinal lumen, conjugated bile salts cross the otherwise impermeable lipid bilayer of (primarily terminal ileal) enterocytes through the apical sodium-dependent bile acid transporter (gene SLC10A2) and leave the enterocyte through the basolateral heteromeric organic solute transporter, which consists of an alpha and beta subunit (encoded by SLC51A and SLC51B). The Na -taurocholate cotransporting polypeptide (gene SLC10A1) efficiently clears the portal circulation of bile salts, and the apical bile salt export pump (gene ABCB11) pumps the bile salts out of the hepatocyte into primary bile, against a very steep concentration gradient. Recently, individuals lacking either functional Na -taurocholate cotransporting polypeptide or organic solute transporter have been described, completing the quartet of bile acid transport deficiencies, as apical sodium-dependent bile acid transporter and bile salt export pump deficiencies were already known for years. Novel pathophysiological insights have been obtained from knockout mice lacking functional expression of these genes and from pharmacological transporter inhibition in mice or humans. Conclusion: We provide a concise overview of the four main bile salt transport pathways and of their status as possible targets of interventions in cholestatic or metabolic disorders.
Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1Ldlr mice.
Porteiro B, Roscam Abbing R, In Het Panhuis W, de Waart D, Duijst S, Bolt I J Lipid Res. 2024; 65(8):100594.
PMID: 39009243 PMC: 11382107. DOI: 10.1016/j.jlr.2024.100594.
Bile salt signaling and bile salt-based therapies in cardiometabolic disease.
Groenen C, Nguyen T, Paulusma C, van de Graaf S Clin Sci (Lond). 2024; 138(1):1-21.
PMID: 38180064 PMC: 10767275. DOI: 10.1042/CS20230934.
Gut liver brain axis in diseases: the implications for therapeutic interventions.
Yan M, Man S, Sun B, Ma L, Guo L, Huang L Signal Transduct Target Ther. 2023; 8(1):443.
PMID: 38057297 PMC: 10700720. DOI: 10.1038/s41392-023-01673-4.
Yin J, Zhao Z, Huang J, Xiao Y, Rehmutulla M, Zhang B Cell Discov. 2023; 9(1):77.
PMID: 37488127 PMC: 10366100. DOI: 10.1038/s41421-023-00578-4.
The regulatory role of bile acid microbiota in the progression of liver cirrhosis.
Zhu F, Zheng S, Zhao M, Shi F, Zheng L, Wang H Front Pharmacol. 2023; 14:1214685.
PMID: 37416060 PMC: 10320161. DOI: 10.3389/fphar.2023.1214685.